作者: Jinghua Jiao , Yuheng Wang , Xiaofeng Sun , Xiaojing Jiang
DOI: 10.1155/2017/3826506
关键词: Sedation 、 Pharmacology 、 Agonist 、 Cancer cell 、 Bioinformatics 、 Neuraxial blockade 、 Midazolam 、 Adjuvant 、 Cancer 、 Mechanism (biology) 、 Medicine
摘要: With its high worldwide mortality and morbidity, cancer has gained increasing attention novel anticancer drugs have become the focus for research. Recently, studies shown that most anesthetic agents can influence activity of tumor cells. Midazolam is a γ-aminobutyric acid A ( ) receptor agonist, used widely preoperative sedation as an adjuvant during neuraxial blockade. Some indicated potential midazolam therapeutic drug; however, mechanism by which affects cells needs to be clarified. This systematic review aims summarize progress in assessing molecular agent.